Viatris (VTRS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.69
- Estimate
- $0.60
- Surprise
- +15.0%
- Revenue (period 2026-06-30)
- $3.75B
- Score today
- 5.7/10
Revenue source: xbrl.
How the report landed
Viatris (VTRS) beat the $0.60 estimate with diluted EPS of $0.69 — a large 15.0% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates VTRS Sell at 5.7/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +15.0% surprise compares with a +12.1% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Target reached (-1.6% upside)
- Quality below floor (3.9 < 4.0)
- Negative risk/reward — downside exceeds upside
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $16.45
- Price target
- $16.93
- Stop
- $15.65
- Upside to target
- +2.9%
Risk check: trading volume is running 1.6× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
VTRS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $18.96B
- P/E (fwd)
- 6.2
- 52-week range
- $9.43–$18.39
- Off 52-week high
- 10.5%
- RSI (14)
- 54
- Volume vs avg
- 1.64×
- Score today
- 5.7/10